The role of connected cancer data in precision oncology: highlights from GLIOMATCH presentation at EU event
GLIOMATCH coordinator Prof. Frederik De Smet presented how the project connects tumour tissue, imaging and clinical data to understand responses to immunotherapy and support precision oncology for patients with brain tumours.
GLIOMATCH: Explained with Dr. Kathrin Cresswell
In this episode of the GLIOMATCH: Explained video series, Dr. Kathrin Cresswell, Professor of Digital Innovations in Health and Care at the University of Edinburgh, explains how GLIOMATCH is working to ensure the successful use and implementation of its novel data platform. We’ve summarised the interview in this news piece.
GLIOMATCH shares its work at the EU Cancer Mission Showcase in Brussels
On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.
Highlights from partner talks at EANO 2026
The KU Leuven team attended EANO 2026 in Rome and Chiara Caprioli and Frederik De Smet presented glioblastoma research and a patient-derived brain tumour model. Discover highlights from the conference.
Presenting research on radiotherapy resistance in paediatric glioma at SIOPE BTG 2026
At the SIOPE Brain Tumour Group Annual Meeting 2026, KU Leuven researcher Julie Morscio discussed how patient-derived tumour models can help investigate why diffuse midline glioma cells survive radiotherapy. Read her testimonial.
Childhood Cancer Awareness Month 2026: Spotlight on GLIOMATCH’s paediatric glioma research
On International Childhood Cancer Day, GLIOMATCH highlights the urgent need for research into paediatric high-grade gliomas (pHGGs), rare and aggressive brain tumours affecting children. With a median survival of just over one year and no curative treatment available, collaborative research efforts are essential to better understand the disease, develop dedicated models, and tailor therapies that improve outcomes and quality of life for young patients and their families.
GLIOMATCH: Explained with Dr. Chiara Caprioli and Prof. Frederik De Smet
In this GLIOMATCH: Explained episode, Dr. Chiara Caprioli and Prof. Frederik De Smet from KU Leuven explain how new research has mapped the evolution of glioblastoma from diagnosis to recurrence, identified distinct tumour trajectories and established a framework that could support more personalised treatment decisions.
GLIOMATCH: Explained with Prof. Dr. Sandra Jacobs
In this GLIOMATCH: Explained episode, Prof. Dr. Sandra Jacobs introduces the paediatric clinical study, the participating centres and the challenges of working with archived samples from paediatric high-grade glioma patients.
GLIOMATCH marks World Brain Tumour Day at EU event on advancing brain cancer research
On World Brain Tumour Day 2026, GLIOMATCH participated in the European event “Advancing Brain Cancer Research: From policy action to scientific breakthroughs” at the European Parliament in Strasbourg. The event highlighted the urgent need to accelerate brain cancer research, strengthen European collaboration and turn scientific progress into improved care for patients.
GLIOMATCH: Explained with Prof. Dr. Steven De Vleeschouwer
In this GLIOMATCH: Explained episode, Prof. Dr. Steven De Vleeschouwer introduces the prospective clinical trials, the participating centres and the immunotherapy strategies being investigated to better understand patient response in brain tumours.